Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


15.05.2017

2 AJNR Am J Neuroradiol
1 BMC Neurol
1 Clin Exp Immunol
6 J Neuroimmunol
1 J Neurol
3 J Neurol Sci
1 J Neurosci Res
1 Magn Reson Med
5 Mult Scler
3 Neurology
1 Neurosci Lett
1 PLoS One
1 Rev Neurol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJNR Am J Neuroradiol

  1. FORSLIN Y, Shams S, Hashim F, Aspelin P, et al
    Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study.
    AJNR Am J Neuroradiol. 2017 May 11. doi: 10.3174/ajnr.A5211.
    PubMed     Text format     Abstract available

  2. WANG W, van Heerden J, Tacey MA, Gaillard F, et al
    Neuroradiologists Compared with Non-Neuroradiologists in the Detection of New Multiple Sclerosis Plaques.
    AJNR Am J Neuroradiol. 2017 May 4. doi: 10.3174/ajnr.A5185.
    PubMed     Text format     Abstract available


    BMC Neurol

  3. SHIRANI A, Newton BD, Okuda DT
    Finger tapping impairments are highly sensitive for evaluating upper motor neuron lesions.
    BMC Neurol. 2017;17:55.
    PubMed     Text format     Abstract available


    Clin Exp Immunol

  4. KARNELL FG, Lin D, Motley S, Duhen T, et al
    Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation.
    Clin Exp Immunol. 2017 May 12. doi: 10.1111/cei.12985.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  5. KINOSHITA M, Daifu M, Tanaka K, Tanaka M, et al
    Prognostic value of oligoclonal IgG bands in Japanese clinically isolated syndrome converting to clinically definite multiple sclerosis.
    J Neuroimmunol. 2017;307:1-6.
    PubMed     Text format     Abstract available

  6. SERAFINI B, Scorsi E, Rosicarelli B, Rigau V, et al
    Massive intracerebral Epstein-Barr virus reactivation in lethal multiple sclerosis relapse after natalizumab withdrawal.
    J Neuroimmunol. 2017;307:14-17.
    PubMed     Text format     Abstract available

  7. SAUER EL, Trifilieff E, Greer JM
    Predicting the effects of potentially therapeutic modified peptides on polyclonal T cell populations in a mouse model of multiple sclerosis.
    J Neuroimmunol. 2017;307:18-26.
    PubMed     Text format     Abstract available

  8. ZAHOOR I, Haq E
    Multiple sclerosis in India: Iceberg or volcano.
    J Neuroimmunol. 2017;307:27-30.
    PubMed     Text format     Abstract available

  9. FERNANDO KTM, James M
    Early predictors of rapidly evolving multiple sclerosis: A case report.
    J Neuroimmunol. 2017;307:42-46.
    PubMed     Text format     Abstract available

  10. LIU G, Zhang F, Hu Y, Jiang Y, et al
    Multiple sclerosis risk pathways differ in Caucasian and Chinese populations.
    J Neuroimmunol. 2017;307:63-68.
    PubMed     Text format     Abstract available


    J Neurol

  11. LATTANZI S, Cagnetti C, Danni M, Provinciali L, et al
    Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis.
    J Neurol. 2017 May 10. doi: 10.1007/s00415-017-8505.
    PubMed     Text format     Abstract available


    J Neurol Sci

  12. TRENTINI A, Castellazzi M, Romani A, Squerzanti M, et al
    Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients.
    J Neurol Sci. 2017;377:133-136.
    PubMed     Text format     Abstract available

  13. CALABRO RS, Russo M, Naro A, De Luca R, et al
    Robotic gait training in multiple sclerosis rehabilitation: Can virtual reality make the difference? Findings from a randomized controlled trial.
    J Neurol Sci. 2017;377:25-30.
    PubMed     Text format     Abstract available

  14. AGLIARDI C, Guerini FR, Zanzottera M, Rovaris M, et al
    Indoleamine-2,3-dioxygenase(IDO)2 polymorphisms are not associated with multiple sclerosis in Italians.
    J Neurol Sci. 2017;377:31-34.
    PubMed     Text format     Abstract available


    J Neurosci Res

  15. JUREWICZ A, Domowicz M, Galazka G, Raine CS, et al
    Multiple sclerosis: Presence of serum antibodies to lipids and predominance of cholesterol recognition.
    J Neurosci Res. 2017 May 8. doi: 10.1002/jnr.24062.
    PubMed     Text format     Abstract available


    Magn Reson Med

  16. BY S, Barry RL, Smith AK, Lyttle BD, et al
    Amide proton transfer CEST of the cervical spinal cord in multiple sclerosis patients at 3T.
    Magn Reson Med. 2017 May 5. doi: 10.1002/mrm.26736.
    PubMed     Text format     Abstract available


    Mult Scler

  17. SHINODA K, Matsushita T, Nakamura Y, Masaki K, et al
    HLA-DRB1*04:05 allele is associated with intracortical lesions on three-dimensional double inversion recovery images in Japanese patients with multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707067. doi: 10.1177/1352458517707067.
    PubMed     Text format     Abstract available

  18. ZEYDAN B, Lowe VJ, Schwarz CG, Przybelski SA, et al
    Pittsburgh compound-B PET white matter imaging and cognitive function in late multiple sclerosis.
    Mult Scler. 2017 May 1:1352458517707346. doi: 10.1177/1352458517707346.
    PubMed     Text format     Abstract available

  19. FREILICH J, Manouchehrinia A, Trusheim M, Baird LG, et al
    Characterization of annual disease progression of multiple sclerosis patients: A population-based study.
    Mult Scler. 2017 May 1:1352458517706252. doi: 10.1177/1352458517706252.
    PubMed     Text format     Abstract available

  20. BENEDICT RH, Cohan S, Lynch SG, Riester K, et al
    Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Mult Scler. 2017 May 1:1352458517707345. doi: 10.1177/1352458517707345.
    PubMed     Text format     Abstract available

  21. GOVEROVER Y, Chiaravalloti N, Genova H, DeLuca J, et al
    A randomized controlled trial to treat impaired learning and memory in multiple sclerosis: The self-GEN trial.
    Mult Scler. 2017 May 1:1352458517709955. doi: 10.1177/1352458517709955.
    PubMed     Text format     Abstract available


    Neurology

  22. ESHAGHI A, Ciccarelli O
    Author response: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    

  23. AVASARALA J
    Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    

  24. ARNOLD DL, Fisher E, Brinar VV, Cohen JA, et al
    Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003169.
    PubMed     Text format     Abstract available


    Neurosci Lett

  25. SZALARDY L, Zadori D, Bencsik K, Vecsei L, et al
    Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis.
    Neurosci Lett. 2017 May 5. pii: S0304-3940(17)30386.
    PubMed     Text format     Abstract available


    PLoS One

  26. CHARVET LE, Yang J, Shaw MT, Sherman K, et al
    Cognitive function in multiple sclerosis improves with telerehabilitation: Results from a randomized controlled trial.
    PLoS One. 2017;12:e0177177.
    PubMed     Text format     Abstract available


    Rev Neurol

  27. ALCALA-VICENTE C, Perez-Miralles FC, Gascon-Gimenez F, Bosca-Blasco I, et al
    [Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice].
    Rev Neurol. 2017;64:445-453.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: